SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines

Cancer Letters

Volumn 237, Issue 1, 2006, Pages 143-154

  Ryu, Ji Kon ^a   Lee, Woo Jin ^a   Lee, Kwang Hyuck ^a   Hwang, Jin Hyeok ^a   Kim, Yong Tae ^a   Yoon, Yong Bum ^a   Kim, Chung Yong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Apoptosis; Cell cycle; Histone deacetylase inhibitor; Pancreatic cancer; SK 7041

Indexed keywords

CYCLIN B1; CYCLIN D2; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P21; SK 7041; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; G2 PHASE; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33646533106     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.040     Document Type: Article

References (30)

1. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97 (2000) 10014-10019
2. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 287-299
3. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2001) 287-299
4. Qiu L., Burgess A., Fairlie D.P., Leonard H., Parsons P.G., and Gabrielli B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 11 (2000) 2069-2083
5. Donadelli M., Costanzo C., Faggioli L., Scupoli M.T., Moore P.S., Bassi C., et al. an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 38 (2003) 59-69
6. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 96 (1996) 4592-4597
7. Kim D.K., Lee J.Y., Kim J.S., Ryu J.H., Choi J.Y., Lee J.W., et al. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J. Med. Chem. 46 (2003) 5745-5751
8. Park J.H., Jung Y., Kim T.Y., Kim S.G., Jong H.S., Lee J.W., et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10 (2004) 5271-5281
9. Donadelli M., Costanzo C., Faggioli L., Scupoli M.T., Moore P.S., Bassi C., et al. an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 38 (2003) 59-69
10. Sato N., Ohta T., Kitagawa H., Kayahara M., Ninomiya I., Fushida S., et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol. 24 (2004) 679-685
11. Coffey D.C., Kutko M.C., Glick R.D., Butler L.M., Heller G., Rifkind R.A., et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61 (2001) 3591-3594
12. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasm. Clin. Cancer Res. 8 (2002) 718-728
13. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
14. Wittich S., Scherf H., Xie C., Brosch G., Loidl P., Gerhauser C., et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 45 (2002) 3296-3309
15. Xiao H., Hasegawa T., and Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73 (1999) 291-302
16. Yamashita Y., Shimada M., Harimoto N., Rikimaru T., Shirabe K., Tanaka S., et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 103 (2003) 572-576
17. Peart M.J., Tainton K.M., Ruefli A.A., Dear A.E., Sedelies K.A., O'Reilly L.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63 (2003) 4460-4471
18. 2-M transition. Biochem. Biophys. Res. Commun. 310 (2003) 267-273
19. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 344 (1990) 503-508
20. Lallemand F., Courilleau D., Buquet-Fagot C., Atfi A., and Montagne M.N. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Cell Res. 247 (1999) 432-440
21. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 (1994) 551-555
22. Meyyappan M., Wong H., Hull C., and Riabowol K.T. Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol. Cell. Biol. 18 (1998) 3163-3172
23. Matsubayashi H., Sato N., Fukushima N., Yeo C.J., Walter K.M., Brune K., et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin. Cancer Res. 9 (2003) 1446-1452
24. Hague A., Diaz G.D., Hicks D.J., Krajewski S., Reed J.C., and Paraskeva C. Bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int. J. Cancer 72 (1997) 898-905
25. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., and Smythe W.R. Histone deacetylase inhibitor down regulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell. Mol. Biol. 25 (2001) 562-568
26. Bernhard D., Skvortsov S., Tinhofer I., Hubl H., Greil R., Csordas A., et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 8 (2001) 1014-1021
27. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3 (2004) 425-435
28. Doi S., Soda H., Oka M., Tsurutani J., Kitazaki T., Nakamura Y., et al. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol. Cancer Ther. 3 (2004) 1397-1402
29. Herold C., Ganslmayer M., Ocker M., Hermann M., Geerts A., Hahn E.G., et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36 (2002) 233-240
30. Glaser K.B., Li J., Pease L.J., Staver M.J., Marcotte P.A., Guo J., et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 325 (2004) 683-690